Genetic variation profiling of 100 important pharmacogenes in the Bruneian population
Pharmacogenomics or the associations between genetic traits of individuals and their responses to drugs is believed to hold the key to the solution of low (30 to 60%) pharmaceutical efficacy observed in many of today’s drug treatments. In ASEAN, information pertaining to the prevalence of pharmacogenomic biomarkers is incomplete. Individual case safety reports (adverse effects or drug-related problems) per million population per year range from ~3600 in Singapore to just 9 in Brunei. Therefore, an ASEAN-wide pharmacogenomics consortium has recently been tasked to fill in the gap. As a collaborative project between ASEAN countries and RIKEN (Japan), the initial study will involve the next-generation sequencing of 100 important pharmacogenes in 1000 individuals across the 10 ASEAN nations. In Brunei, DNA from 100 anonymous healthy individuals will be extracted and the 100 pharmcogenes library constructed for sequencing at RIKEN. Genetic variations identified here and those from other ASEAN individuals will aid in the estimation of allelic frequencies of genotypic biomarkers of drug metabolisers. Such information should ultimately provide the important scientific support on the wider implementation of pharmacogenomic screening in Brunei and ASEAN using a customised pharmacogene panel.
Application invited for: PhD/Master by research